Diagnostic Sensitivity of [18F]-Florbetaben-PET/CT in Detecting Cardiac Involvement in AL Amyloidosis Authors: Paolo Milani, Giuseppe Damiano Sanna, Giovanna Pepe, Adele Valentini, Giovanni Matassa, Gianluigi Guida, Roberta Mussinelli, Marco Basset, Annalisa Turco, Stefano Perlini, Alessandra Greco, Sandra Schirinzi, Mario Nuvolone, Emilio Bassi, Michela Zacchino, Andrea Foli, Giampaolo Merlini, Leonardo De Luca, Lorenzo Preda, Giovanni Palladini Published: 2026 ABSTRACT AbstractBackgroundEarly detection of cardiac involvement in light-chain (AL) amyloidosis remains challenging despite its prognostic importance. [18F]-florbetaben positron emission tomography/computed-tomography (F-PET) shows promise for amyloid detection.ObjectivesThe authors report results from the prospective MoRBiDA (Molecular, magnetic resonance, and echocardiographic imaging combined with biomarkers of cardiac and clonal disease to predict survival and assess response to therapy in cardiac AL amyloidosis) study integrating multimodality imaging in treatment-naive AL amyloidosis patients to evaluate F-PET diagnostic sensitivity and correlations with established markers.MethodsPatients with suspected cardiac involvement underwent baseline echocardiography, cardiac magnetic resonance (CMR), and F-PET. Cardiac involvement was defined by consensus criteria. F-PET included 50-minute dynamic cardiac acquisition (static reconstructions at ∼15 and 50-min postinjection), delayed static scan at 110 min, and myocardial tracer retention. Positive uptake was defined by visual myocardial retention exceeding blood-pool/background plus quantitative mean and maximum standardized uptake value.ResultsOf the 28 enrolled patients, 25 had cardiac involvement (3 patients without cardiac involvement had no myocardial-uptake). Early and late F-PET uptake (15-50 min) was present in all 25. Delayed uptake (110 min) was absent in 4/25 (84% sensitivity); these showed retention up to 50-min with typical CMR findings. F-PET parameters correlated moderately with N-terminal pro–B-type natriuretic peptide (standardized uptake value rho = 0.40-0.54, P < 0.05) and echocardiographic global longitudinal strain (myocardial tracer retention rho = 0.70, P < 0.001) but not with CMR-derived extracellular volume.ConclusionsEarly-to-late F-PET demonstrates excellent sensitivity for cardiac AL amyloidosis. Delayed (110-min) retention is not universal, indicating variable washout kinetics that limits its discriminatory value for amyloid typing vs late imaging or multiorgan analysis. Extracellular volume may not fully capture amyloid burden. These findings complement recent multicentric data and support further studies on optimal timing and volumetric metrics.Key words: amyloidosis, diagnosis, [18F]-florbetaben Light chain (AL) amyloidosis is caused by a small B-cell clone responsible for the production of monoclonal immunoglobulin light chains that deposit in the form of amyloid fibrils in the interstitium of target organs where they also exert direct cellular toxicity.1,2 In AL amyloidosis, cardiac involvement is the main determinant of prognosis and survival.3 Therefore, its early identification is critical although challenging, as cardiac involvement may be clinically silent at the time of diagnosis or mimic other causes of increased left ventricular (LV) wall thickness.4 Echocardiography often represents the first imaging modality in the diagnostic work-up of amyloid heart involvement in the majority of patients; however, its performance in terms of tissue characterization is limited.5, 6, 7 Cardiac magnetic resonance (CMR) provides advanced tissue characterization; native myocardial T1 mapping, extracellular volume (ECV), and late gadolinium enhancement (LGE) have shown a potential ability to differentiate conditions characterized by thickened hearts (eg, higher values in AL amyloidosis).8 However, it is still not possible to definitively distinguish the amyloid type based solely on CMR data, despite few reports have addressed this issue.9 Amyloid deposits identification and typing in tissue biopsies are still mandatory in all patients with AL amyloidosis, and in approximately 15% to 18% of patients with transthyretin (ATTR) amyloidosis and a monoclonal protein detected in serum and urine.2,10 Nuclear imaging techniques have transformed the diagnostic approach to systemic amyloidosis, allowing the nonbiopsy diagnosis of ATTR amyloidosis with cardiac involvement with the identification of the 99m-technetium-labeled bone tracers cardiac uptake (grade ≥2), after the exclusion of a monoclonal component by immunofixation in both serum and urine and a free light chain ratio within the normal range.2,11 However, these tracers are not able to identify cardiac involvement in most patients with AL amyloidosis, and they do not allow to differentiate between AL amyloidosis and ATTR amyloidosis or other mimicking conditions. In this context, positron emission tomography (PET) with amyloid-binding tracers has emerged as promising tool.12 Among these, 18-F florbetapir and the 18-F florbetaben have shown the capacity of the identification of cardiac amyloid involvement.13,14 Moreover, the potential ability of 18-F florbetaben in the differential diagnosis between cardiac involvement by AL amyloidosis or ATTR amyloidosis has been reported,14 and a phase III trial is ongoing to further clarify this aspect (NCT05184088). Recent whole-body [18F]-florbetaben PET/computed tomography (F-PET) studies further suggest that combining cardiac and extracardiac uptake (eg, lung, salivary glands) improves differentiation of AL from ATTR cardiac amyloidosis.15 Beyond detection, both tracers have shown their potential role in disease prognosis and monitoring.16,17 Accordingly, we focus here on F-PET as a novel imaging approach to identify and characterize cardiac involvement in AL amyloidosis. MoRBiDA (Molecular, magnetic resonance, and echocardiographic imaging combined with biomarkers of cardiac and clonal disease to predict survival and assess response to therapy in cardiac AL amyloidosis) is a prospective study integrating multimodality imaging with detailed cardiac and hematologic phenotyping in newly diagnosed AL amyloidosis. Here, we report the preliminary findings of the MoRBiDA study. Methods Study design and participants MoRBiDA was a single-center interventional clinical study involving newly diagnosed treatment-naive patients with AL amyloidosis and suspected cardiac involvement. Aims of the MoRBiDA study were: 1) the evaluation of diagnostic sensitivity and prognostic relevance of advanced imaging variables (for echocardiography global longitudinal strain (GLS); for CMR native T1, T2, ECV, indexed volumes, LV mass and ejection fraction [EF]; for F-PET myocardial uptake scores), and their correlations with established markers of prognosis; 2) the use of the aforementioned imaging variables in the assessment of treatment response; and 3) the evaluation of the clinical impact of amyloid deposits assessed by imaging and the toxicity of the circulating amyloid precursor on the severity of cardiac involvement, on cardiac response, and on outcome. This present analysis of baseline data is aimed at evaluating the diagnostic sensitivity of F-PET in newly-diagnosed patients with AL amyloidosis and cardiac involvement according to established diagnostic criteria.18 All participants provided written informed consent before enrollment, and the local institutional review board approved the study, which was registered on www.clinicaltrials.gov (NCT04392960). Inclusion criteria were: 1) newly diagnosed treatment-naive AL amyloidosis; 2) age >18 years; 3) histological diagnosis of AL amyloidosis; 4) measurable potential cardiac involvement as per current response criteria (i.e., N-terminal pro–B-type natriuretic peptide [NT-proBNP] >650 ng/L); 5) measurable hematologic disease (difference between involved and uninvolved free light chains >20 mg/L); 6) estimated glomerular filtration rate (eGFR) > 30 mL/min per 1.73 m2; 7) absence of atrial fibrillation with uncontrolled heart rate; 8) absence of cardiac implantable electronic devices or prostheses; 9) absence of pulmonary amyloidosis histologically documented; 10) plan to start antiplasma cell chemotherapy; 11) plan to assess response at the Pavia center after 6 months; and 12) written informed consent to participate. Exclusion criteria were: 1) non-AL amyloidosis; 2) NYHA functional class IV; 3) Eastern Cooperative Oncology Group Performance Status Scale >3; 4) severe allergy to paramagnetic tracer; 5) any known contraindication to CMR scan; and 6) pregnancy or lactation. Patients were enrolled between January 2020 and December 2023. Diagnosis of AL amyloidosis All patients had a biopsy-proven diagnosis of AL amyloidosis, and the deposits were characterized as AL-type by immunoelectron microscopy, and/or mass spectrometry analysis.10,19, 20, 21 In all cases, DNA analysis was performed to exclude hereditary forms due to mutations in TTR and APOA1 genes encoding ATTR and apolipoprotein A-I, respectively, as previously described.22 Organ involvement was defined according to the current consensus criteria.18,23 Cardiac staging was defined according to the modified Mayo 2004 staging system24 and subsequent modifications.25,26 All the study patients underwent a baseline comprehensive clinical (including detailed medical history and physical examination), laboratory, and instrumental evaluation. Laboratory tests Laboratory tests included cardiac biomarkers (NT-proBNP and high sensitivity troponin I). Serum creatinine was measured, and eGFR was calculated with the Chronic Kidney Disease Epidemiology Collaboration equation.27 Instrumental evaluation Echocardiography Echocardiographic examinations were performed using a ACUSON SC2000 Prime cardiovascular ultrasound system (SIEMENS Healthineers) equipped with a 1.1 to 4.9 MHz transducer. A comprehensive transthoracic examination was performed in the left-lateral decubitus position. Doppler tracings and 2-dimensional images were obtained from parasternal long- and short-axis, apical, and subcostal views. In the presence of irregular heart rhythm (eg, atrial fibrillation), multiple loops (at least five) and averaged measurements were obtained. Standard cardiac chamber quantification was performed in accordance with current American Society of Echocardiography and European Association of Cardiovascular Imaging recommendations.28 LV volumes were calculated from apical 4-chamber and 2-chamber views. LV GLS values were obtained from apical 3-chamber, 4-chamber, and 2-chamber views. Cardiac magnetic resonance CMR was performed on a 1.5-T magnet (MAGNETOM Aera, Siemens Healthcare). All patients underwent a standard protocol, including LGE for eGFR >30 mL/min. More in detail, each scan included. •Balanced steady-state free-precession cine images for LV volumes, mass, and EF quantification; Balanced steady-state free-precession cine images for LV volumes, mass, and EF quantification; •Modified Looked Locker inversion recovery sequence before and 15 minutes after 0.15 mmol/kg of contrast (Gadovist; Bayer Schering Pharma) for T1 mapping. T1 maps were acquired in basal and mid-ventricular short axis and 4 chambers view;29 Modified Looked Locker inversion recovery sequence before and 15 minutes after 0.15 mmol/kg of contrast (Gadovist; Bayer Schering Pharma) for T1 mapping. T1 maps were acquired in basal and mid-ventricular short axis and 4 chambers view;29 •T2-prepared True- Fast Imaging with Steady-State Precession for T2 mapping acquired before contrast medium administration in basal and mid-ventricular short-axis and 4-chambers view; normal T1/T2 values of our laboratory were used as reference (T2: males 45 ± 2 (43-47) ms, females 48 ± 4 (44-52) ms; Modified Looked Locker inversion recovery sequence T1: males 983 ± 50 (933-1,033) ms, female 1,015 ± 34 (981-1,049) ms; T2-prepared True- Fast Imaging with Steady-State Precession for T2 mapping acquired before contrast medium administration in basal and mid-ventricular short-axis and 4-chambers view; normal T1/T2 values of our laboratory were used as reference (T2: males 45 ± 2 (43-47) ms, females 48 ± 4 (44-52) ms; Modified Looked Locker inversion recovery sequence T1: males 983 ± 50 (933-1,033) ms, female 1,015 ± 34 (981-1,049) ms; •Two-dimensional phase-sensitive inversion recovery LGE images 10 min after contrast. The LGE pattern was classified into 3 groups according to the degree of transmurality: group 1, no LGE; group 2, subendocardial LGE; and group 3, transmural LGE.30,31 Two-dimensional phase-sensitive inversion recovery LGE images 10 min after contrast. The LGE pattern was classified into 3 groups according to the degree of transmurality: group 1, no LGE; group 2, subendocardial LGE; and group 3, transmural LGE.30,31 All CMR images and maps were analyzed offline. In addition to all usual morphological and functional variables, LGE was quantified on short-axis stacks using a semiautomatic approach. For ECV measurement, a single region of interest was drawn in each of the 4 required areas: basal to mid-septum in 4-chamber map for myocardial T1 estimate, and LV cavity blood pool in 4-chamber map before and after contrast administration for blood T1 estimates. ECV was calculated as: myocardial ECV = (1 − hematocrit) × (ΔR1myocardium/ΔR1blood), where ΔR1 = 1/T1. 18F-florbetaben positron emission tomography/computed tomography All patients underwent F-PET. The first 10 studies used a GE Discovery ST8 scanner; subsequent studies (from April 2021) used a Siemens Biograph 64 mCT with 3D acquisition. No dietary or medication restrictions were applied. The mean injected activity was 376 ± 70 MBq. A low-dose computed tomography was acquired for attenuation correction. Mean standardized uptake value (SUV) (SUVmean) and maximum SUV (SUVmax) for the whole heart and segments were calculated on early (5-15 min), late (50-60 min) scans, as well as on static images obtained at 110 min (delayed), according to preexisting literature. A 2-min upper-abdomen static scan followed for kidney assessment. Subsequent acquisitions included total body PET at 70 min and brain PET at 90 min. PET data were reconstructed with OSEM (4 iterations, 12 subsets). Qualitative assessment was visual (myocardial uptake > blood-pool/background on static images). Semiquantitative analysis used standardized uptake values (SUVmean and SUVmax) for the whole heart and segments. Percentage myocardial tracer retention (MTR) was calculated from dynamic images as: Positive myocardial uptake was defined as visually increased retention relative to blood pool/background on early/intermediate images, confirmed by elevated SUV values. The same color scale was applied across time points for consistency. The software used for uptake quantitation was the Siemens Healthineers Syngo.via vb80 in all cases. Interobserver agreement was assessed by two board-certified nuclear medicine physicians (G.P. and G.M.), who independently delineated the regions of interest and measured SUVmean and SUVmax values in the entire heart as well as in the basal septum, mid-septum, and apex on the 15-, 50-, and 110-minute PET images. Statistical analysis All variables were tested for normality by Shapiro-Wilk test plus visual inspection of histograms/Q-Q plots. Results were expressed as mean ± SD (or median and IQR) for continuous variables, or as number of cases and percentage for categorical variables. The Student’s t-test and Mann-Whitney U test or the chi-square test were used to compare the differences between 2 groups. The relationship between specific continuous variables was analyzed, and Spearman’s (ρ) correlation coefficients obtained. Spearman’s correlation coefficients (rho) were interpreted using the following standard thresholds: rho <0.30 = weak, 0.30 to 0.49 = moderate, 0.50 to 0.69 = strong, and ≥0.70 = very strong. A P value <0.05 was considered statistically significant. Given the exploratory nature of the correlation analyses, we applied the Benjamini-Hochberg false discovery rate (FDR) procedure to control for multiple testing. Statistical analysis of agreement included calculation of the mean difference ± SD, paired t-test for systematic bias, Pearson’s correlation coefficient, intraclass correlation coefficient for absolute agreement (two-way mixed-effects model), and Bland-Altman analysis. Sensitivity analyses were performed by excluding the 3 patients without cardiac involvement according to consensus criteria. Statistical analyses were performed using MedCalc Statistical Software (version 22.016, MedCalc Software Ltd). Results Patient characteristics A total of 28 patients were enrolled in the study (Table 1). Twenty-five (89%) patients had cardiac involvement according to the established international diagnostic criteria. The 3 patients without cardiac involvement (elevated biomarkers attributed to prior ischemic disease) showed no myocardial F-PET uptake at any time point (early, intermediate, or delayed), supporting the absence of cardiac amyloid. In these 3 patients, echocardiography and CMR were also not suggestive for AL cardiac amyloidosis. Table 1Clinical, Laboratory, and Instrumental Features of the Study PopulationAll Patients Enrolled (N = 28)Patients With Heart Involvement According to Echo and CMR (n = 25)Patients With Heart Involvement According to All Methods (n = 21)Age, y66 (60-72)66 (61-72)68 (62-72)Male19 (68)16 (64)14 (66)Organ involvement Heart25 (89)25 (100)21 (100) Kidney19 (68)17 (68)15 (71) Liver/ST1 (3.5)/1 (3.5)—/1 (4)—/1 (4) ANS/PNS1 (3.5)/—1 (4)/—1 (4)/— Other2 (7)1 (4)1 (4) >2 organs2 (7)2 (8)2 (9)PS-ECOG 0, 1, 29 (32), 17 (60), 2 (7)8 (32), 15 (60), 2 (8)7 (33), 12 (57), 2 (9)NYHA functional class, I, II, III11 (39), 14 (50), 3 (10)9 (36), 13 (52), 3 (12)7 (33), 11 (52), 3 (14)NT-proBNP, ng/L2,725 (1,637-4,193)3,298 (1,642-4,327)3,697 (2,248-4714)Hs-cTnI, ng/L57 (32-134)60 (34-154)69 (35-155)Cardiac stage II, IIIa, IIIb21 (75), 6 (21), 1 (3.5)18 (72), 6 (24), 1 (4)13 (62), 7 (33), 1 (5)Renal stage, I, II, III19 (68), 9 (32), −16 (64), 9 (36), —15 (71), 6 (29), —dFLC, mg/L315 (145-441)311 (123-441)311 (151-441)Kappa:lambdaκ = 9: λ = 19κ = 6: λ = 19κ = 6/λ = 15BMPC, %15 (10-25)15 (9-22)15 (10-22)Echocardiographic data IVSd, mm15 (13-17)15 (13-17)15 (13-18) PWd, mm13 (12-15)13 (12-14)13 (12-14) LVEF, %54 (51-59)56 (50-63)55 (49-63) GLS, %−14 (−16 to −10)−14 (−16 to −10)−14 (−16 to −9)CMR data: T1 mapping (ms)1,141 (1,109-1,171)1,156 (1,110-1,175)1,156 (1,109-1,175) ECV (%)48 (43-58)50 (45-56)51 (45-56) T2 mapping (ms)52.3 (51-53)53 (51-53)53 (51-53)Values are n (%) or median (IQR). Cardiac stage25 based on troponin level and NT-proBNP: thresholds for cTnI (or hs-cTnI) and NT-proBNP are <0.1 ng/mL (<77 ng/L), and <332 ng/L, respectively. Stage IIIa is defined at a cTnI >0.1 ng/mL or a hs-cTnI>77 ng/L, and NT-proBNP >332 ng/L (provided their NT-proBNP is <8,500 ng/L). Stage IIIb are stage IIIa with NT-proBNP >8,500 ng/L. Stage II patients have 1 value of either troponin or NT-proBNP above the thresholds. Stage I patients have troponin and NT-proBNP below the thresholds. Renal stage32 based on proteinuria and eGFR levels: thresholds for proteinuria >5 g/24 h and eGFR <50 mL/min/1.73 m2. Stage I, both proteinuria ≤5 g/24 h and eGFR ≥50 mL/min/1.73 m2; stage II, either proteinuria >5 g/24 h or eGFR <50 mL/min per 1.73 m2; stage III, both proteinuria >5 g/24 h and eGFR <50 mL/min/1.73 m2.ANS = autonomic nervous system; BMPC = bone marrow plasma cell infiltrate; CMR = cardiac magnetic resonance; dFLC = difference between involved and uninvolved free light chains; ECOG-PS = Eastern Cooperative Oncology Group – Performance Status; ECV = extra-cellular volume; GLS = global longitudinal strain; hs-cTnI = high sensitivity troponin I; IVSd = diastolic interventricular septum thickness; LVEF = left ventricular ejection fraction; NT-proBNP = N-terminal pro B-type natriuretic peptide; PNS = peripheral nervous system; PWd = diastolic posterior wall; ST = soft tissue; extra-cardiac uptake that should be described: 5 lung-uptake; 5 thyroid gland uptake; 3 bowel-uptake; 1 spleen. Clinical, Laboratory, and Instrumental Features of the Study Population Values are n (%) or median (IQR). Cardiac stage25 based on troponin level and NT-proBNP: thresholds for cTnI (or hs-cTnI) and NT-proBNP are <0.1 ng/mL (<77 ng/L), and <332 ng/L, respectively. Stage IIIa is defined at a cTnI >0.1 ng/mL or a hs-cTnI>77 ng/L, and NT-proBNP >332 ng/L (provided their NT-proBNP is <8,500 ng/L). Stage IIIb are stage IIIa with NT-proBNP >8,500 ng/L. Stage II patients have 1 value of either troponin or NT-proBNP above the thresholds. Stage I patients have troponin and NT-proBNP below the thresholds. Renal stage32 based on proteinuria and eGFR levels: thresholds for proteinuria >5 g/24 h and eGFR <50 mL/min/1.73 m2. Stage I, both proteinuria ≤5 g/24 h and eGFR ≥50 mL/min/1.73 m2; stage II, either proteinuria >5 g/24 h or eGFR <50 mL/min per 1.73 m2; stage III, both proteinuria >5 g/24 h and eGFR <50 mL/min/1.73 m2. ANS = autonomic nervous system; BMPC = bone marrow plasma cell infiltrate; CMR = cardiac magnetic resonance; dFLC = difference between involved and uninvolved free light chains; ECOG-PS = Eastern Cooperative Oncology Group – Performance Status; ECV = extra-cellular volume; GLS = global longitudinal strain; hs-cTnI = high sensitivity troponin I; IVSd = diastolic interventricular septum thickness; LVEF = left ventricular ejection fraction; NT-proBNP = N-terminal pro B-type natriuretic peptide; PNS = peripheral nervous system; PWd = diastolic posterior wall; ST = soft tissue; extra-cardiac uptake that should be described: 5 lung-uptake; 5 thyroid gland uptake; 3 bowel-uptake; 1 spleen. Diagnostic sensitivity of F-PET in detecting cardiac involvement in AL amyloidosis The 3 patients without cardiac involvement (elevated biomarkers attributed to prior ischemic disease) showed no myocardial F-PET uptake at any time point (early, late, or delayed), supporting the absence of cardiac amyloid. Early-to-late F-PET uptake (15-50 minutes postinjection) was present in all 25 patients with confirmed cardiac involvement, corresponding to 100% diagnostic sensitivity (95% CI: 86.3%-100%) (Figure 1, Central Illustration). Exclusion of the 3 patients without cardiac involvement did not change the primary result (100% sensitivity of early-to-late F-PET uptake). In contrast, delayed uptake at 110 minutes was absent in 4/25 patients (16%) (Table 2, Figure 2). These 4 patients showed clear MTR on reprocessed images from the dynamic acquisition in the 30 to 45 minutes window and exhibited typical features of cardiac amyloidosis on CMR, including elevated native T1 mapping and diffuse subendocardial or transmural LGE. No significant differences in clinical characteristics, biomarkers, echocardiographic parameters, or CMR variables were found between the 21 patients with persistent delayed uptake and the 4 patients without delayed uptake (Supplemental Tables 1 and 2). Comprehensive quantitative data (SUVmean and SUVmax) for the whole heart and myocardial segments at all 3 time points (15, 50, and 110 min) are reported in Table 2. Imaging Assessment of a Patient With Delayed [18F]-Florbetaben Positron Emission Tomography/Computed Tomography Uptake (A) Echocardiography. Parasternal long-axis view showing increased wall thickness (IVSd >12 mm, PWd >12 mm). (B) Echocardiography. Left ventricular filling pattern; mitral inflow demonstrates a high E-wave velocity with a small A-wave velocity, and E/A >>2. (C) CMR. Late gadolinium enhancement (LGE) with phase-sensitive inversion recovery (PSIR) reconstruction (left ventricular short-axis view mid-level). Extensive and diffuse subendocardial LGE mainly involving infero-lateral the right side of the interventricular septum. (D to F) F-PET images. Diagnostic Sensitivity of [18F]-Florbetaben Positron Emission Tomography/Computed Tomography in Detecting Cardiac Involvement in Light-Chain Amyloidosis CMR = cardiac magnetic resonance; F-PET = [18F]-florbetaben positron emission tomography/computed tomography; PET/CT = positron emission tomography/computed tomography. Table 2[18F]-Florbetaben Positron Emission Tomography/Computed Tomography DataAll Patients Enrolled (N = 28)Patients With Heart Involvement According to Echo and CMR (n = 25)Patients With Heart Involvement According to All Methods (n = 21)Entire heart Early scan (5-15 min) SUVmean5.1 (3.1-6.8)5.7 (4.0-7.0)5.8 (4.2-7.4) SUVmax9.0 (5.3-12.8)9.3 (6.4-13.3)9.5 (7.1-14.3) Late scan (50-60 min) SUVmean3.8 (2.3-6.5)5.1 (2.8-6.5)6.2 (3.5-6.6) SUVmax8.4 (4.7-12.4)9.1 (5.0-13.6)10.6 (6.1-15.6) Delayed static scan (110 min) SUVmean3.7 (2.4-7.9)4.0 (3.0-8.1)5.2 (3.2-8.2) SUVmax6.6 (4.2-13.4)7.9 (5.1-13.8)9.6 (5.4-14.2)Heart basal septum Early scan (5-15 min) SUVmean5.0 (3.3-5.9)4.8 (3.7-6.2)4.9 (3.9-6.7) SUVmax6.4 (4.1-7.6)6.6 (4.6-8.0)6.8 (5.4-9.4) Late scan (50-60 min) SUVmean3.8 (2.2-6.0)4.1 (2.3-6.3)5.1 (2.8-7.1) SUVmax5.0 (2.6-8.5)6.0 (3.0-8.9)7.6 (3.3-9.1) Delayed static scan (110 min) SUVmean3.4 (2.2-7.3)3.8 (2.7-7.4)4.9 (2.9-7.4) SUVmax4.4 (2.9-9.3)4.8 (3.3-9.8)6.5 (4.2-10.2)Heart middle septum Early scan (5-15 min) SUVmean7.2 (4.2-9.5)6.5 (4.2-7.7)7.0 (4.8-8.2) SUVmax7.2 (4.2-9.5)7.8 (5.0-9.7)8.3 (5.2-9.9) Late scan (50-60 min) SUVmean5.6 (2.6-9.6)5.4 (2.8-8.3)6.5 (3.8-8.7) SUVmax5.6 (2.6-9.6)7.0 (3.3-10.1)8.1 (4.9-10.5) Delayed static scan (110 min) SUVmean4.1 (2.3-8.4)4.4 (3.0-9.6)5.8 (3.5-9.9) SUVmax4.7 (2.8-10.4)5.5 (3.9-12.2)6.9 (4.2-12.3)Heart apex portion Early scan (5-15 min) SUVmean5.5 (3.6-6.8)5.8 (4.3-7.3)5.9 (5.2-8.7) SUVmax6.7 (4.4-8.5)7.4 (5.6-8.9)7.6 (6.1-10.0) Late scan (50-60 min) SUVmean4.3 (2.6-6.7)4.9 (3.0-6.9)6.2 (3.9-7.4) SUVmax5.3 (3.1-8.9)6.1 (3.4-9.2)7.1 (4.6-9.4) Delayed static scan (110 min) SUVmean3.7 (2.7-7.8)4.3 (2.7-8.0)4.8 (3.5-8.5) SUVmax4.7 (3.1-9.4)5.4 (3.3-9.6)5.9 (4.0-10.2)MTR, %78 (70-97)77 (70-99)88 (71-103)Values are median (IQR).MTR = myocardial tracer retention; SUVmax = maximum standardized uptake value; SUVmean = mean standardized uptake value; other abbreviation as in Table 1. [18F]-Florbetaben Positron Emission Tomography/Computed Tomography Data Values are median (IQR). MTR = myocardial tracer retention; SUVmax = maximum standardized uptake value; SUVmean = mean standardized uptake value; other abbreviation as in Table 1. Imaging Assessment of a Patient With NO-Delayed [18F]-Florbetaben Positron Emission Tomography/Computed Tomography Uptake (A) Echocardiography. Parasternal long-axis view showing markedly increased wall thickness (IVSd 16 mm, PWd 16 mm). (B) Echocardiography. Left ventricular filling pattern; mitral inflow demonstrates a high E-wave velocity with a small A-wave velocity, and E/A ∼2. (C) CMR data. Late gadolinium enhancement (LGE) with phase-sensitive inversion recovery (PSIR) reconstruction (left ventricular short-axis view mid-level). Extensive subendocardial LGE also involving the right side of the interventricular septum and papillary muscles. (D to F) F-PET images. Interobserver agreement for the myocardial F-PET uptake measurements was evaluated between two independent observers (physicians G.P. and G.M.). Excellent interobserver agreement was observed across 424 paired measurements (mean difference +0.024; paired t-test P = 0.538; Pearson r = 0.981; intraclass correlation coefficient = 0.981). The high concordance likely reflects the homogeneous and visually unequivocal myocardial uptake patterns in this AL cohort together with standardized region of interest placement by experienced nuclear medicine physicians. Bland-Altman plots (Supplemental Figure 1) confirmed narrow limits of agreement with no systematic bias or proportional error. Correlations between multimodality imaging parameters and cardiac biomarkers In the subset cohort of 25 patients with heart involvement according to the established criteria, there were moderate positive correlations between NT-proBNP levels and SUV parameters (rho = 0.40-0.54, all P < 0.05 after FDR correction), but not between high sensitivity troponin I concentration and SUV as detailed in Supplemental Table 3. Myocardial tracer retention was not correlated with NT-proBNP levels (rho 0.36, P = 0.076). CMR features (ie, ECV, native T1 and T2) were not associated with the levels of cardiac biomarkers. All reported significant correlations remained significant after correction; nonsignificant findings were unchanged after FDR correction. Correlations between F-PET and echocardiographic parameters The strongest correlation was found between MTR and GLS, which was very strong (rho 0.70, P < 0.001), whereas no correlation was revealed between any partial SUV assessment and GLS as detailed in Supplemental Table 4. A moderate positive correlation was found between SUV and diastolic interventricular septum thickness, whereas no association was detected between F-PET parameters and diastolic posterior wall and EF (Supplemental Table 4). Correlations between F-PET and CMR parameters We did not find any association between F-PET parameters and CMR-derived ECV. There was a moderate and statistically significant association between SUV and native T1. We did not find any association between F-PET parameters and native T2 (Supplemental Table 5). F-PET parameters according to cardiac staging There were no significant differences in terms of any F-PET parameters between patients with cardiac stage II and III (all P > 0.05) (Supplemental Table 6). Among the different multimodality imaging parameters, CMR native T2 (used as an index of myocardial edema) resulted to be significantly higher in patients with a cardiac stage III. Discussion Early-to-late F-PET uptake (15-50 minutes postinjection) demonstrated 100% sensitivity for detecting cardiac involvement in this prospective cohort of treatment-naive patients with AL amyloidosis. This finding is in agreement and extends prior reports on the tracer’s high avidity for AL amyloid deposits while providing the first multimodality validation in a well-characterized, prospectively enrolled population studied at diagnosis. The key novel observation is the heterogeneity in delayed retention at 110 minutes: 16% of patients (4/25) lacked visually detectable myocardial uptake at the 110-minute static acquisition despite clear retention on images from the dynamic acquisition in the early-to-late window and classic CMR features of amyloidosis (elevated native T1 and diffuse subendocardial/transmural LGE). These 4 “delayed-negative” cases did not significantly differ clinically, echocardiographically, or on CMR from the 21 patients with persistent 110-minute uptake, suggesting variable washout kinetics rather than absent tracer binding. This kinetic nuance has direct implications for image interpretation and amyloid typing. Previous studies, including Genovesi et al, proposed that sustained uptake across both late (30-45/50-60 minutes) and delayed (110 minutes) windows could discriminate AL from ATTR cardiac amyloidosis and nonamyloid phenocopies. The present data indicate that although retention through the early-to-late (15-50-minute) window appears universal in AL disease, persistence to 110 minutes is not. Consequently, reliance on a single very-late static acquisition may underestimate AL amyloidosis involvement and reduce the discriminatory capacity of delayed imaging. Our findings align with and complement the recent multicentric CAPRI study (Sprauel et al), which demonstrated that whole-body F-PET at an earlier 10–30-minute window, when combined with extracardiac uptake patterns (lung and salivary glands) and myocardial uptake volume, correctly classified 93% of patients as AL vs ATTR amyloidosis with heart involvement. Until data from ongoing comparative studies including patients with ATTR cardiac amyloidosis become available (eg, the phase III trial [NCT05184088]), the present findings support the excellent sensitivity of early-to-late (15-50 min) F-PET for detecting cardiac involvement in patients with confirmed systemic AL amyloidosis. These results should be interpreted within the context of a well-characterized AL amyloidosis cohort and do not yet allow definitive noninvasive differential diagnosis of amyloid type in isolation; integration with clinical, laboratory, and other imaging data remains essential. Although the current AL amyloidosis cohort did not include an ATTR amyloidosis comparator, the universal early/intermediate uptake observed here supports the notion that optimized timing (intermediate window) or multiorgan analysis enhances diagnostic performance beyond cardiac-only delayed imaging. F-PET parameters showed moderate positive correlations with NT-proBNP (SUV rho 0.40-0.54, all P < 0.05) and with GLS (MTR rho = 0.70, P < 0.001), consistent with the tracer’s ability to reflect amyloid-related cardiac stress and mechanical dysfunction. The absence of correlation between F-PET parameters and CMR-derived ECV may have underlying biological explanations. ECV quantifies the total ECV expansion, which in AL amyloidosis can be the result not only of amyloid deposits but also of interstitial edema, inflammation, and reactive fibrosis driven by direct light-chain toxicity. In contrast, [18F]-florbetaben potentially binds directly to the amyloid fibrils. Variable fibril composition, density, and distribution in AL amyloidosis, together with the toxic effects of circulating free light chains on cardiomyocytes, may therefore decouple amyloid burden (as measured by PET) from overall extracellular expansion (as measured by ECV). This dissociation highlights the complementary information provided by the 2 modalities. Study limitations This single-center study is limited by its relatively small sample size (N = 28, with 25 patients demonstrating cardiac involvement), which significantly limits statistical power and the robustness of the conclusions, with a CI for diagnostic sensitivity wide at the lower bound; therefore, potential sensitivity assumptions should be interpreted with caution. Because of the study design focused on patients with suspected cardiac involvement and the small number of true-negative cases, specificity, predictive values, and receiver operating characteristic analysis could not be meaningfully estimated. The absence of an ATTR amyloidosis comparator group precludes direct assessment of amyloid typing; therefore, statements regarding the discriminatory value of delayed uptake must be interpreted within this context. Not all patients underwent endomyocardial biopsy for histologic confirmation of cardiac amyloid burden. Volumetric metrics (eg, cardiac amyloid activity or % injected dose) and full kinetic modeling of the dynamic data were not evaluated, as the study was designed to evaluate diagnostic sensitivity in a homogeneous AL amyloidosis cohort; these approaches may further refine diagnostic performance and prognostic assessment in future studies. Conclusions In this prospective single-center study of treatment-naive patients with AL amyloidosis, early-to-late F-PET/CT (15-50 min) demonstrated encouraging sensitivity for detecting cardiac involvement. However, myocardial uptake on delayed static imaging at 110 min was not universal, indicating heterogeneous tracer washout kinetics. This finding suggests that reliance on a single very-late acquisition may be suboptimal for diagnosis or amyloid typing and supports the use of earlier imaging windows or integrated multiorgan assessment. These data support the clinical utility of optimized F-PET protocols for sensitive detection of cardiac AL amyloidosis. However, they do not yet permit definitive noninvasive differentiation from ATTR amyloidosis or other hypertrophic cardiomyopathies. Integration with clinical, laboratory, and multimodal imaging findings remains essential until comparative data from ATTR cohorts become available. Larger multicenter studies incorporating volumetric quantification and kinetic modeling are needed to further define the diagnostic and prognostic role of this technique. Funding support and author disclosures This work was supported by the Italian Ministry of Health, Ricerca Corrente, project code 927-rcr2018i-73. Dr Milani has received honoraria from Janssen, Prothena, Pfizer (also research grant), Siemens, and Bayer (also served on advisory board). Dr Sanna has received Cardiac ATTR Amyloidosis fellowship grant funded by International Society of Amyloidosis (2023-2024); honoraria for lectures and teaching courses; and travel support to attend scientific meetings from Alnylam, Astra Zeneca, Bayer, and Pfizer. Dr Mussinelli has received speaker honoraria and travel grants from Alnylam, AstraZeneca, and Pfizer. Dr Perlini served on advisory board of and received travel grants and speaker honoraria from Pfizer, Alnylam, Bayer, Accurate, and AKCEA. Dr Basset was partially supported by “Prof. Franco Mandelli fellowship award” by the Italian Society of Hematology (SIE) and AIL. Dr Palladini has received honoraria from Pfizer, Sebia, and Siemens; and served on advisory boards Alexion, Argobio, GSK, Janssen, and Prothena. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Acknowledgments The authors thank patients, investigators, and study coordinators Dr Anna Carnevale Baraglia and Elone Luka. Footnotes The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center. Appendix For supplemental tables and figures, please see the online version of this paper. Supplementary material Supplemental Material References Associated Data Supplementary Materials Supplemental Material